Pros | ![]() Among most bought funds within the category. ![]() Larger AUM within category. ![]() Beats FD returns for both 3Y & 5Y duration. | ![]() 5Y returns in the top 25% of the category. ![]() 3Y returns in the top 25% of the category. ![]() Beats FD returns for both 3Y & 5Y duration. | ||
Cons | - | - |
INDMoney rank | 7/8 | 1/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 12 Years | 12 Years | ||
Fund Size | 8161 Cr | 3522 Cr | ||
Min Investment | SIP ₹100 Lumpsum ₹5000 | SIP ₹500 Lumpsum ₹5000 | ||
Expense Ratio | 0.93% | 0.89% | ||
Exit Load | 1% | 0.5% | ||
Benchmark Index | S&P BSE Healthcare PR | S&P BSE Healthcare PR |
No of Holdings | 38 | 32 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (13.52%) Divi's Laboratories Ltd (9.65%) Lupin Ltd (7.61%) Cipla Ltd (5.5%) Apollo Hospitals Enterprise Ltd (5.13%) | Sun Pharmaceuticals Industries Ltd (12.87%) Divi's Laboratories Ltd (6.42%) Cipla Ltd (5.68%) Max Healthcare Institute Ltd Ordinary Shares (5.66%) Lupin Ltd (4.74%) | ||
No of Sectors | 1 | 2 | ||
Top 3 Sectors | Health (100%) | Health (93.18%) Basic Materials (6.82%) | ||
Equity % | 96.93% | 96.5% | ||
Debt % | - | - | ||
P/E | 37.43 | 44.54 | ||
P/B | 6.11 | 6.28 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | -7.46% | -5.62% | ||
3-Month Return | -6.32% | -3.52% | ||
6-Month Return | -4.7% | 4.71% | ||
1-Year Return | 11% | 19.47% | ||
3-Year Return | 19.19% | 23.62% | ||
5-Year Return | 24.96% | 26.71% |
Sharpe | 0.87 | 1.24 | ||
Alpha | -0.03 | 5.14 | ||
Beta | 0.93 | 0.84 | ||
Standard Deviation | 15.2 | 13.86 | ||
Information Ratio | -0.32 | 1.01 |
Description | Nippon India Pharma Fund - Direct Plan - Growth Plan is an equity fund.The fund could potentially beat inflation in the long-run. | SBI Healthcare Opportunities Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Kinjal Desai,Sailesh Raj Bhan | Tanmaya Desai |